

Foreword to second edition	11
Foreword to first edition	12
Preface to second edition	13
Glossary and abbreviations	15
Introduction	21
I Background information on tuberculosis and human immunodeficiency virus	23
1.1 Tuberculosis	23
1.1.1 Basic facts about TB	23
1.1.2 Pathogenesis of TB	25
1.2 Human immunodeficiency virus	27
1.2.1 Introduction: HIV and AIDS	27
1.2.2 HIV/AIDS epidemiology	28
1.2.3 HIV transmission	28
1.2.4 Prevention of HIV transmission in health units	29
1.2.5 Immunopathogenesis of HIV infection	30
1.2.6 Natural history of HIV infection	31
1.2.7 Clinical staging	32
1.2.8 Epidemiological surveillance of AIDS	35
1.3 HIV-related TB	36
1.3.1 Epidemiology of coinfection of HIV and <i>M tuberculosis</i>	36
1.3.2 HIV infection and risk of TB	37
1.3.3 TB in the course of HIV progression	37
1.3.4 Consequence of HIV/ <i>M tuberculosis</i> coinfection	37
1.3.5 Impact of HIV on TB control	37
1.3.6 Patterns of HIV-related TB	38
1.3.7 Impact of TB on HIV	39
2 An expanded framework for effective tuberculosis control	41
2.1 Introduction	41
2.2 Components of expanded TB control framework	41
2.2.1 Goals of TB control	42
2.2.2 Targets for TB control (cure and case detection)	42
2.2.3 TB control policy package (the DOTS strategy)	43

2.2.4	Key operations for DOTS implementation.	44
2.2.5	Indicators to measure NTP progress in TB control	45
2.3	Directly observed treatment	45
2.4	TB/HIV	46
2.5	DOTS-Plus.	47
3	Diagnosis of pulmonary tuberculosis in adults	49
3.1	Diagnostic approach	49
3.2	Clinical features	50
3.3	Diagnostic sputum smear microscopy	51
3.4	Differential diagnosis of pulmonary TB.	54
3.5	Chest X-ray in diagnosis	55
3.6	Radiographic abnormalities seen in pulmonary TB	55
3.7	Differential diagnosis of chest X-ray findings	56
3.8	The place of mycobacterial culture in the diagnosis of TB	57
3.9	Sepsis and concomitant TB	57
3.10	Distinguishing other HIV-related pulmonary diseases from pulmonary TB	58
4	Diagnosis of pulmonary tuberculosis in children	61
4.1	Epidemiology of childhood TB	61
4.2	How does TB in children differ from TB in adults?	62
4.3	Approach to diagnosis of TB	63
4.4	Score system for diagnosis of TB in children	66
4.5	Tuberculin skin test	67
4.6	The decision to start TB treatment in children	68
4.7	Impact of HIV on the diagnosis of TB in children	69
4.8	Differential diagnosis of pulmonary TB in HIV-infected children	70
4.9	Management of child contacts of infectious adults	71
5	Diagnosis of extrapulmonary tuberculosis in adults and children	75
5.1	Diagnostic approach	75
5.2	Tuberculous lymphadenopathy	75
5.3	Miliary (disseminated) TB.	78
5.4	Tuberculous serous effusions (pleural, pericardial, ascites)	79
5.5	Tuberculous meningitis.	84
5.6	Other forms of extrapulmonary TB.	87
5.7	Further information on spinal, gastrointestinal and hepatic TB.	88

6	Diagnosis of HIV infection in adults with tuberculosis	91
6.1	Clinical recognition of HIV infection in TB patients	91
6.2	HIV testing	92
6.2.1	HIV antibody tests	92
6.2.2	Tests to detect the virus itself	93
6.2.3	Objectives of HIV antibody testing in TB patients	94
6.2.4	Strategy for HIV antibody testing in TB patients	94
6.2.5	Diagnosis of HIV infection in individual TB patients	95
6.3	HIV counselling	95
7	Diagnosis of HIV infection in children with tuberculosis	99
7.1	Clinical recognition of HIV infection in children with TB	99
7.2	HIV testing	100
7.3	Counselling	101
8	Standardized tuberculosis case definitions and treatment categories	105
8.1	Standardized case definitions	105
8.1.1	Introduction	105
8.1.2	Questions and answers about case definitions	105
8.1.3	Case definitions by site and result of sputum smear	106
8.1.4	Category of TB patient for registration on diagnosis	107
8.2	Standardized diagnostic categories	108
9	Management of patients with tuberculosis	111
9.1	Introduction	111
9.2	Modes of action of anti-TB drugs	112
9.3	TB treatment regimens	113
9.3.1	New cases	114
9.3.2	Re-treatment cases	114
9.3.3	Standard code for TB treatment regimens	114
9.3.4	Recommended treatment regimens	115
9.3.5	Use of streptomycin in areas of high HIV prevalence	117
9.3.6	Use of TB drugs in children	117

9.4	TB treatment regimens: questions and answers	118
9.5	Use of anti-TB drugs in special situations	120
9.6	The role of adjuvant steroid treatment: questions and answers	121
9.7	Monitoring of TB patients during treatment.	122
9.7.1	Monitoring of patients with sputum smear-positive PTB	122
9.7.2	Recording treatment outcome	123
9.7.3	Cohort analysis: questions and answers	124
9.8	Response of HIV-positive TB patients to anti-TB treatment	124
10	Side-effects of anti-tuberculosis drugs	129
10.1	Introduction.	129
10.2	Prevention of side-effects	129
10.3	Where to manage drug reactions	129
10.4	When to stop anti-TB drugs	129
10.5	Side-effects of anti-TB drugs	130
10.5.1	Side-effects of anti-TB drugs in HIV-positive TB patients	131
10.6	Symptom-based approach to management of drug side-effects.	132
10.7	Management of skin itching and rash	132
10.7.1	Treatment regimen includes thioacetazone	133
10.7.2	Treatment regimen does not include thioacetazone.	133
10.8	Desensitization	134
10.9	Management of hepatitis	135
11	Antiretroviral therapy for the treatment of HIV infection	137
11.1	Introduction.	137
11.2	Antiretroviral drugs	138
11.3	Principles of ART	138

11.4	Principles of a public health approach to ART	139
11.5	Initiation of ART	139
11.5.1	Adults and adolescents with documented HIV infection	140
11.5.2	Infants and children	140
11.6	Recommended doses of ARV drugs	141
11.6.1	Adults and adolescents	141
11.6.2	Children.	142
11.7	Choice of ART regimen	149
11.7.1	Adults	149
11.7.2	Children.	150
11.8	Monitoring the efficacy of ART.	151
11.9	Adverse effects	151
11.10	Interactions between ARV drugs and drugs used to prevent or treat opportunistic infections	153
11.11	Antiretroviral drugs and TB treatment	153
11.11.1	Drug interactions.	153
11.11.2	Treating TB and HIV together	153
11.11.3	Immune reconstitution syndrome	154
11.11.4	Options for ART in patients with TB	154
12	Treatment and prevention of other HIV-related diseases in TB/HIV patients	157
12.1	Introduction.	157
12.2	Clinical spectrum of HIV-related disease	157
12.3	Sexually transmitted infections.	158
12.3.1	Syndromic management.	158
12.3.2	Treatment regimens for common STIs.	159
12.4	Skin and mouth problems	161
12.5	Respiratory problems	165
12.5.1	Respiratory problems in adults	165
12.5.2	Respiratory problems in children.	167
12.6	Gastrointestinal problems	167
12.6.1	Dysphagia.	167
12.6.2	Diarrhoea in adults	168
12.6.3	Diarrhoea in children.	170

12.7	Neurological problems in adults	171
12.7.1	Acute confusion	171
12.7.2	Chronic behaviour change	172
12.7.3	Persistent headache	172
12.7.4	Difficulty in walking	174
12.7.5	Poor vision	175
12.7.6	Burning sensation in the feet	175
12.8	Neurological problems common in children	175
12.9	Fever	176
12.9.1	Approach to management	176
12.9.2	Disseminated infection	176
12.10	Other HIV-related problems	177
12.11	Prevention of HIV-related opportunistic infections	179
12.11.1	General measures	179
12.11.2	Immunizations	179
12.11.3	Primary chemoprophylaxis in adults	180
12.11.4	Primary chemoprophylaxis in children	181
12.11.5	Secondary chemoprophylaxis in adults	181
13	Coordinated care in different settings	185
13.1	Introduction	185
13.2	The expanded scope of a new approach to decrease the burden of TB/HIV	185
13.3	Referral to local HIV/AIDS care services	186
13.4	Benefits of support from local HIV/AIDS care services	186
13.5	A framework for HIV/AIDS care that incorporates interventions to address TB	187
13.5.1	Home and community care	187
13.5.2	Primary care	188
13.5.3	Secondary care	189
13.5.4	Tertiary care	189
13.6	The private sector	191
13.6.1	Private medical practitioners	191
13.6.2	Traditional practitioners	191
13.7	Operational research aimed at improving integrated TB and HIV/AIDS prevention and care	192

13.7.1	Promoting voluntary counselling and testing (VCT) for HIV as an entry point to better TB care	192
13.7.2	The Practical Approach to Lung Health (PAL)	192
14	Prevention of tuberculosis in HIV-infected individuals	195
14.1	Introduction	195
14.2	Protection of HIV-positive persons against exposure to TB	195
14.2.1	Environmental control	195
14.2.2	Face-masks	196
14.2.3	Patient education	196
14.2.4	Pulmonary TB suspects	196
14.2.5	Patients with sputum smear-positive pulmonary TB	197
14.2.6	Patients with multidrug-resistant TB (MDR-TB)	197
14.3	Role of BCG in preventing TB in HIV-infected individuals.	197
14.3.1	Background	197
14.3.2	BCG protection against TB in HIV-infected children.	198
14.3.3	BCG safety in HIV-infected children	198
14.3.4	WHO recommended policy on BCG and HIV.	198
14.4	The role of the Expanded Programme on Immunization (EPI)	199
14.5	Preventive treatment	199
14.5.1	Target groups for preventive treatment	200
14.5.2	Role of isoniazid preventive treatment in HIV-positive individuals	201
14.5.3	WHO/UNAIDS recommendations on preventive therapy against TB in HIV-positive persons.	201
	Index	205